<?xml version="1.0" encoding="UTF-8"?>
<fig id="fig02" fig-type="figure" orientation="portrait" position="float">
 <label>Fig. 2.</label>
 <caption>
  <p>Systemic H84T treatment is highly efficacious against lethal influenza virus infection in mice. (
   <italic>A</italic>–
   <italic>C</italic>) Therapeutic efficacy of H84T administered intraperitoneally in BALB/c mice challenged intranasally with two times the 50% mouse lethal dose of A/WSN/HA(NC/2099-N225G)/1933 (H1N1). (
   <italic>A</italic>) Survival of mice following intraperitoneal treatment with H84T (0.15–5 mg/kg) once daily for 5 d beginning 4 h postchallenge. (
   <italic>B</italic>) Survival of mice following intraperitoneal treatment with H84T (5 mg/kg) once daily for 5 d beginning 4, 24, 48, or 72 h postchallenge, or treatment with oseltamivir (10 mg/kg) beginning 4 or 72 h postchallenge. (
   <italic>C</italic>) Survival of mice following intraperitoneal treatment with H84T (50 mg/kg) on a single occasion 21 d before challenge, then once daily for 5 d (5 mg/kg/d) beginning 4 h postchallenge. Placebo mice received PBS 21 d prechallenge and once daily for 5 d beginning 4 h postchallenge. (
   <italic>D</italic>) Therapeutic efficacy of H84T administered subcutaneously in BALB/c mice challenged intranasally with a lethal dose of A/WSN/HA(NC/2099-N225G)/1933 (H1N1). Survival of mice following subcutaneous treatment with a regimen of either one or two 50-mg/kg doses of H84T within 4 d postinfection. *
   <italic>P</italic> &lt; 0.05, **
   <italic>P</italic> &lt; 0.01, ***
   <italic>P</italic> &lt; 0.001, and ****
   <italic>P</italic> &lt; 0.0001. Kaplan–Meier survival curves for 
   <italic>A</italic> to 
   <italic>D</italic> were compared by the log-rank (Mantel–Cox) test followed by pairwise comparison using the Gehan–Breslow–Wilcoxon test.
  </p>
 </caption>
 <graphic id="gra2" xlink:href="pnas.1915152117fig02" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
